Stereotactic tenecteplase clot liquefaction for supratentorial intracerebral hemorrhage

Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage

This trial will see if stereotactic minimally invasive clot drainage plus a single low dose of tenecteplase helps adults with moderate-to-large supratentorial intracerebral hemorrhage recover better than standard medical care.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 768 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Tongji Hospital (Academic / other)
• Locations: 2 sites (Suzhou, Anhui and 1 other locations)
• Trial ID: NCT07208097 on ClinicalTrials.gov

What this trial studies

This phase III, prospective, multicenter, open-label randomized controlled trial with blinded endpoint assessment will enroll 768 adults with spontaneous supratentorial intracerebral hemorrhage and randomize them 1:1 to stereotactic minimally invasive puncture plus tenecteplase liquefaction drainage (single 0.5 mg TNK dose) or to standard medical management. Eligible patients must present within 24 hours of symptom onset with hematoma volumes of 25–60 mL, NIHSS ≥6, GCS 9–14, and pre-stroke mRS ≤1. The intervention aims to speed hematoma liquefaction and drainage to reduce secondary brain injury and improve outcomes. Clinical outcomes will be adjudicated by blinded assessors to limit bias.

Who should consider this trial

Good fit: Ideal candidates are adults 18–80 years old with spontaneous supratentorial ICH presenting within 24 hours, hematoma volume 25–60 mL, NIHSS ≥6, GCS 9–14, and pre-stroke mRS ≤1 who can consent and attend follow-up.

Not a fit: Patients with brainstem or cerebellar hemorrhages, very small or very large hematomas outside the 25–60 mL range, severe coma, contraindications to thrombolytics or invasive procedures, or late presentation (>24 hours) are unlikely to benefit.

Why it matters

Potential benefit: If successful, the approach could speed clot removal, lower early mortality, and improve functional recovery after intracerebral hemorrhage.

How similar studies have performed: Minimally invasive evacuation combined with rt‑PA or urokinase has shown safety and reduced mortality but not consistent functional improvement, and tenecteplase is promising in ischemic stroke but largely untested for ICH in large randomized trials.

Eligibility criteria

Inclusion Criteria ：

1. . Age 18 to 80 years, any gender.
2. . Clinically confirmed acute spontaneous supratentorial intracerebral hemorrhage (ICH), with diagnostic CT completed within 24 hours of symptom onset (for patients with unknown time of onset or wake-up stroke, the time from the last known well to symptom detection is used as the presumed onset time).
3. . CT-confirmed supratentorial ICH with hematoma volume calculated by ABC/2 method between 25 mL and 60 mL (inclusive).
4. . National Institutes of Health Stroke Scale (NIHSS) score ≥ 6.
5. .Glasgow Coma Scale (GCS) score between 9 and 14 (inclusive).
6. . Pre-stroke modified Rankin Scale (mRS) score ≤ 1.
7. . Good compliance, with written informed consent provided by the patient and/or legal guardian, and ability to adhere to the scheduled follow-up visits.

Exclusion Criteria：

1. . Brainstem or cerebellar hemorrhage; or thalamic hemorrhage with significant midbrain shift accompanied by third nerve palsy or unreactive dilated pupils.
2. . Irreversible brainstem dysfunction (bilateral fixed, dilated pupils and decerebrate posturing).
3. . Secondary ICH caused by: head trauma, arteriovenous malformation (AVM), moyamoya disease, intracranial aneurysm, coagulation disorders (hereditary or acquired hemorrhagic diathesis, hemophilia, coagulation factor deficiency, leukemia, etc.), hemorrhagic transformation of cerebral infarction, or tumor; multiple intracranial hemorrhages, subarachnoid hemorrhage (SAH), primary intraventricular hemorrhage, drug-induced hemorrhagic stroke, subdural hemorrhage, epidural hemorrhage.
4. . Significant abnormalities in the following laboratory parameters:(1)International normalized ratio (INR) \> 1.4; any irreversible coagulopathy or known coagulation disorder that cannot be corrected with procoagulants to maintain INR ≤ 1.4. (2) Severe hepatic insufficiency: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 3 times the upper limit of normal (ULN). (3) Severe renal insufficiency: estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m². (4)Hemoglobin \< 90 g/L.5）Platelet count \< 100 × 10⁹/L.
5. . History of malignancy, autoimmune diseases (including but not limited to systemic lupus erythematosus, systemic vasculitis), hemorrhagic diathesis (including various hereditary and acquired bleeding disorders), malignant arrhythmias, cardiac insufficiency (B-type natriuretic peptide \[BNP\] ≥ 1000 pg/mL or left ventricular ejection fraction \[LVEF\] ≤ 40%), acute myocardial infarction, acute or severe infectious diseases (e.g., intracranial infection, severe pneumonia, sepsis), or any other severe concurrent illness that may exacerbate the condition or interfere with efficacy assessment.
6. . Known high risk of thromboembolism, including: presence of a mechanical heart valve prosthesis, history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis. (Note: Atrial fibrillation without mitral stenosis is permitted).
7. . Myocardial infarction within 30 days prior to randomization.
8. .Use of anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, apixaban) within 1 week prior to symptom onset.
9. . History of internal bleeding (e.g., gastrointestinal bleeding, genitourinary bleeding, retroperitoneal bleeding) within 3 months prior to randomization.
10. . Major surgery or vascular puncture (e.g., venesection, arterial puncture) within 3 months prior to randomization.
11. . History of significant head trauma or severe stroke within 3 months prior to randomization.
12. . History of intracerebral hemorrhage within 1 year prior to randomization.
13. . Indications for craniotomy: (1) Progressive impairment of consciousness; (2)Preoperative signs of brain herniation (e.g., foramen magnum herniation, tentorial herniation) posing a life-threatening condition.
14. . Intraventricular hemorrhage (IVH) or ICH with rupture into the ventricle causing intraventricular cast formation and/or hydrocephalus anticipated to require external ventricular drainage (EVD).
15. . Patient or family requests craniotomy or neuroendoscopic surgery for hematoma evacuation.
16. . Pre-randomization decision by patient/family for Do-Not-Resuscitate (DNR) or Do-Not-Intubate (DNI) orders regarding life-sustaining measures.
17. . Known hypersensitivity or intolerance to TNK.
18. . Pregnancy (positive urine pregnancy test) in women of childbearing potential.
19. . Concurrent participation in another investigational drug or device study.
20. . History of drug or alcohol abuse/dependence, severe dementia, or psychiatric disorder prior to randomization, anticipated to result in poor compliance and inability to complete follow-up.

Where this trial is running

Suzhou, Anhui and 1 other locations

• Suzhou First People's Hospital — Suzhou, Anhui, China (Recruiting)
• Guizhou Medical University Affiliated Hospital — Guiyang, Guizhou, China (Active_not_recruiting)

Study contacts

• Study coordinator: Pan Chao, MD, PhD

Conditions Intracerebral Haemorrhage; Minimally Invasive Treatment; intracerebral haemorrhage; minimally invasive treatment; hematoma evacuation; tenecteplase